Therapeutics for Challenging Diseases​

Our current effort on innovative drug development focuses on the M102 program. M102 is a proprietary disease-modifying drug candidate based on recently understood disease pathways in neurogenerative diseases. Neurodegenerative diseases represent a range of medical conditions which primarily affect the neurons in the human brain. Neurons are the building blocks of the nervous system which includes the brain and spinal cord. Normally, neurons do not reproduce or replace themselves, so when they become damaged or dead, they cannot be replaced by the body.